Medical/Pharmaceuticals

Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S.

MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68...

2022-05-30 08:02 4101

MedAlliance's SELUTION SLR drug-eluting balloon (DEB) receives FDA investigational device exemption (IDE) approval, making it the first limus DEB to be available to US patients

GENEVA, May 30, 2022 /PRNewswire/ -- The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent (DES). SELUTION SLR was also the first DEB (Drug Eluting Balloon) granted "breakthrough device de...

2022-05-30 08:00 3678

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

- First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics - - Additional data from ongoing ADG126 clinical program to be presented in second half of 2022, including safety in combination with anti-PD-1 therapies - SAN DIEGO and SUZHOU, Chi...

2022-05-27 09:30 6969

Menarini inaugurates new regional headquarters in Dubai, UAE

The pharmaceutical group, present in 140 countries in the world, aims to raise standard of patient healthcare across theMiddle East and Africa (MEA) region with innovative products and breakthrough research DUBAI, UAE, May 26, 2022 /PRNewswire/ -- Menarini, the leading Italian pharmaceutical gro...

2022-05-26 23:16 4444

US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD

Key Highlights: * US FDA has cleared Cynata's IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company * Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of ne...

2022-05-26 20:44 3547

OLON ANNOUNCES THE CREATION OF A MAJOR CENTER OF RESEARCH AND DEVELOPMENT IN ITALY, THAT WILL GIVE RISE TO AN INNOVATIVE GLOBAL R&D MODEL

MILAN, May 26, 2022 /PRNewswire/ -- Olon, Leading API supplier, announces the creation of an R&D hub at its center inMilan, home to the Group's headquarters, paving the way for further major expansion and diversification of its expertise applied to the development of APIs for the CDMO and Generic...

2022-05-26 19:00 2620

"To China, Empower Your Shared Future" the 2nd Round of CIIE Medtech Roadshow Open for Application Now

SHANGHAI, May 26, 2022 /PRNewswire/ -- "To China, Empower Your Shared Future" the 2nd CIIE Innovation Incubation Area - one of the most distinguished medtech trade show inChina has been officially launched since March, 2022. On the China International Import Expo (CIIE) platform, CIIE Innovation ...

2022-05-26 15:44 3459

DeepGI AI - A Thai Innovation for the Precision in Colorectal Polyp Detection

BANGKOK, May 26, 2022 /PRNewswire/ -- Chula Engineering and Chula Medicine co- invent an innovative device for a rapid gastrointestinal cancer detection that yields accurate results hoping to foster preventive medicine in gastrointestinal malignancy and reduce the number of cancer patients.

2022-05-26 10:10 3655

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data from the global, Phase 3 AGILE trial that demonstrated a statistically significant improvement in eve...

2022-05-26 08:07 3346

TikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONE

STOCKHOLM, May 26, 2022 /PRNewswire/ -- A new study with TikoMed's platform lead clinical drug candidate ILB®, provides positive safety and tolerability results and the first clinical evidence of encouraging clinical efficacy of ILB® in the treatment of amyotrophic lateral sclerosis (ALS). The st...

2022-05-26 03:40 2612

Golden Meditech Stem Cells Responds to Unfounded Accusations

HONG KONG, May 25, 2022 /PRNewswire/ -- On May 25, 2022, Golden Meditech Stem Cells (BVI) Company Limited (the "Company"), would like to respond to the accusations made against the Company in relation to the Company's enforcement of its rights under the Share Charge Agreement between the Company ...

2022-05-25 23:18 5777

Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts

HYDERABAD, India and BOSTON, May 25, 2022 /PRNewswire/ -- Excelra, a leading global data and digital insights organization, today announced a partnership with HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for th...

2022-05-25 23:04 4591

The Centre for Probe Development and Commercialization expands into Asia and executes a development, manufacturing, and clinical supply agreement for 177Lu-PSMA (DGUL) With South Korea-based CellBion

HAMILTON, ON, May 25, 2022 /PRNewswire/ -- The Centre for Probe Development and Commercialization (CPDC) is pleased to announce the initiation of a development, manufacturing, and supply agreement withCellBion for Lu-177-radiolabelled PSMA (DGUL) therapeutic agent. Under the terms of the agreeme...

2022-05-25 21:00 2120

Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic

Includes asymptomatic testing at community-based facilities to prevent widespread transmissions Regular testing for COVID-19, flu, RSV crucial for staying safe as anti-virus restrictions are eased PCR tests will be priced affordably, made possible through Seegene's 20 years of expertise "Full ...

2022-05-25 19:00 3214

Dr Ivan Puah Expands Service To Sports Aesthetics® To Meet Demands Of Sportspeople

Sports aesthetics® is a term coined by Dr Ivan Puah based on the three pillars of combining unique service offerings to help fitness enthusiasts, sportspeople and professional athletes attain their ideal physiques without compromising the quality of their physical health. SINGAPORE, May 25,...

2022-05-25 16:07 3203

DoctorOnCall Inks MoU with (Pertubuhan Doktor-Doktor Islam Malaysia) PERDIM to Bridge Healthcare Providers and Patients Through Digital Platform

The partnership will propel PERDIM's digital healthcare capabilities and increase revenue by offering an online database of healthcare products, services and treatments across the nation. KUALA LUMPUR, Malaysia, May 25, 2022 /PRNewswire/ -- Malaysia's first and largest digital health platform, H...

2022-05-25 11:08 5089

Brii Biosciences to be Added to MSCI China Small Cap Index

DURHAM, N.C. and BEIJING, May 25, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) today announced that it will be added to the MSCI China Small Cap Index, effective as ofHong Kong market close on May 31, 2022. ...

2022-05-25 08:00 6641

CJ BIO and NatureWorks Working Towards a Master Collaboration Agreement to Commercialize Novel Biopolymer Solutions

Companies announce signed letter of intent to collaborate on creating advanced products based on industry-leading Ingeo™ PLA and PHACT® PHA technologies to meet growing demand for sustainable materials across wide array of markets WOBURN, Mass. and PLYMOUTH, Minn., May 25, 2022 /PRNewswire/ -- CJ...

2022-05-25 07:00 4114

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. * The candidate is intended to be used for the treatment of SARS-CoV-2 and its variants, along with other coronaviruses. * ...

2022-05-25 05:00 3709

Vision Impact Institute Joins Partners to Bring Good Vision to Vulnerable Populations in Panama

Joint effort will expand access to vision care and deliver free eye care and services DALLAS, May 25, 2022 /PRNewswire/ -- The Vision Impact Institute (VII) is pleased to join a partnership that brings eye care services to vulnerable populations inPanama. The partnership includes Lions Club Peno...

2022-05-25 03:34 3485
1 ... 324325326327328329330 ... 381